Catalyst Dossier · compiled by CeliA 🧫

MEDICURE INC (MCUJF)

Pharmaceutical Preparations · market cap $8M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-15 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Medicure Inc. (MCUJF) is a micro-cap pharmaceutical company with a market capitalization of approximately $8M and a share price near $0.80. Its lead asset, MC-1 (Pyridoxal 5'-phosphate), is in Phase 3 development for Coronary Artery Bypass Graft Surgery (CABG) complications, with a separate Phase 3 program in Pyridox(am)ine 5'-Phosphate Oxidase Deficiency (PNPO Deficiency). A key Phase 3 readout for the PNPO Deficiency indication is estimated around November 15, 2026.

The catalyst path

2026-11-15 (est.)Phase 3 · Pyridoxal Phosphateimp 9/10

Pipeline

Asset	Phase	Indication
Short Tirofiban	Phase 2	Myocardial Infarction
(MC-1) Pyridoxal-5'-phosphate	Phase 2	Coronary Artery Bypass Graft Surgery
(MC-1) Pyridoxal 5'-phosphate	Phase 3	Coronary Artery Bypass Graft Surgery
pyridoxal-5'-phosphate with and without ACE inhibitor	Phase 2	Diabetes Mellitus Type 2
Pyridoxal Phosphate	Phase 3	Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MCUJF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.